WO2000072854A1 - A dietary supplement containing vanadyl sulfate, alpha-lipoic acid, and taurine - Google Patents

A dietary supplement containing vanadyl sulfate, alpha-lipoic acid, and taurine Download PDF

Info

Publication number
WO2000072854A1
WO2000072854A1 PCT/US2000/015196 US0015196W WO0072854A1 WO 2000072854 A1 WO2000072854 A1 WO 2000072854A1 US 0015196 W US0015196 W US 0015196W WO 0072854 A1 WO0072854 A1 WO 0072854A1
Authority
WO
WIPO (PCT)
Prior art keywords
composition
alpha
lipoic acid
sulfate
taurine
Prior art date
Application number
PCT/US2000/015196
Other languages
French (fr)
Inventor
Linda Pacioretty
Original Assignee
Ashni Naturaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ashni Naturaceuticals, Inc. filed Critical Ashni Naturaceuticals, Inc.
Priority to AU57255/00A priority Critical patent/AU5725500A/en
Publication of WO2000072854A1 publication Critical patent/WO2000072854A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the present ⁇ n ⁇ ention relates generally to dietary supplements and more particularly, to a formulation of ⁇ anadyl sulfate. alpha-hpoic acid, and tau ⁇ ne to augment or normalize cellular t rosine phosphorvlation responses to insulin thereby decreasing catabolic activity in the diabetic state and decreasing serum hpoproteins and maintaining normal bodv weight in diabetic. HIV-infected and healthy humans and animals
  • Insulin binding causes conformational changes in insulin receptor that lead to autophosphorvlation of the receptor and activation of the receptor ' s intrinsic tvrosine kinase activity
  • the function of the tvrosine kinase of insulin receptor is essential for the biological effects of insulin After autophosphorylation, insulin receptor can phosphorvlate the tyrosine residues of several substrates, including insulin
  • receptor substrate (IRS) proteins which in turn can activate downstream signaling molecules in the liver and muscle cells
  • PTP-1 B protein tvrosine phosphatase termed PTP-1 B can terminate the signalling cascade initiated bv insulin b ⁇ removing the phosphate from insulin receptor Studies indicate that
  • NIDDM non-insulin dependent diabetes melhtus
  • Vanadate is known to be an inhibitor of many phosphatases Some researchers have proposed that vanadate administration may mimic the activity of insulin
  • U S patent 5 550 1 13 and U S patent 5 888 993 disclose vanadium salts for blood sugar regulation
  • U S Patent 5 885 980 and U S Patent 5,614,224 disclose vanadium salts for the treatment of diabetes
  • Vanadyl sulfate is not widely used to mimic the activity of insulin because chronic administration of vanadate can be toxic Vanadyl sulfate has been shown to induce chromosomal damage and mitotic recombination in the fruit fly Vanadyl sulfate can induce pulmonary inflammation in rats when inhaled In vitro studies of bovine papilloma virus
  • vanadvl sulfate Given the potential usefulness of vanadvl sulfate in the treatment ot diabetes it would be desirable to administer compositions containing vanadvl sulfate to diabetic patients, HIV- mfected and normal individuals wishing to minimize their risk of developing NEDDM, if the undesirable side effects of vanadate could be avoided
  • a dietary supplement that comprises vanadvl sulfate alpha-hpoic acid, and tau ⁇ ne
  • the present supplement (1) increases cell sensitivity to insulin, (n) maintains normal serum glucose, (in) decreases hypert ⁇ glyce ⁇ demia and/or hpoproteins, and (iv) maintains normal body weight even with consumption of a high fat diet
  • the supplement can be used by normal, healthy individuals as well as diabetics or persons infected with the HIV virus
  • the present invention also provides a method of dietary supplementation in animals which includes administering to an animal suffering symptoms of diabetes a composition including synergisticaliy effective amounts of vanadyl sulfate alpha-hpoic acid and tau ⁇ ne and continuing administration of the composition until the svmptoms are reduced
  • the present inv ention further provides a method of dietary supplementation in animals which includes administering to an animal a composition which includes svnergistically effective amounts of v anadvl sulfate. alpha-hpoic acid and tau ⁇ ne and continuing administration of the composition until normalization of serum glucose is achieved
  • the present invention still further provides a method of dietary supplementation in animals which includes administering to an animal a composition w hich includes synergisticaliy effective amounts of vanadvl sulfate, alpha-hpoic acid and tau ⁇ ne and continuing administration of the composition until normalization of serum t ⁇ glye ⁇ ceds is achieved
  • the present invention additionally provides a method of treating obesity in an animal which includes administering to an animal a composition including synergisticaliy effective amounts of vanadvl sulfate, alpha-hpoic acid and tau ⁇ ne
  • the animal is a mammal selected from the group consisting of humans nonhuman primates, dogs, cats, horses or cattle Administration can be bv anv method available to the skilled artisan, for example, bv oral and by injection routes
  • Figure 1 provides a schematic diagram illustrating, according to the present invention, how the components of the present formulation vanadvl sulfate.
  • alpha-hpoic acid and tau ⁇ ne can act together to enhance augment or 3 pare [modulate 9 ] the effect of insulin on liver, muscle or fat cells
  • the tyrosine kinase signaling pathway is initiated through the interaction of insulin and the insulin receptor (IR), leading to the phosphorylation of insulin receptor PTP-1B can remove the phosphate from insulin receptor, thereby inactivating its kinase activity
  • Vanadvl sulfate can block the activity of phosphatases like
  • the present invention provides a composition that can be taken as a dietary supplement which includes v anadvl sulfate alpha-hpoic acid, and tau ⁇ ne
  • v anadvl sulfate alpha-hpoic acid and tau ⁇ ne
  • Each of these individual components affect the insulin-induced chain of activities to some degree
  • the resulting dietary supplement addresses the decreased insulin sensitivity and secondary pathologies associated with diabetes, HIV infection normal aging and with NIDDM
  • compounds which inhibit PTP- 1 B can be used to prevent and treat obesitv diabetes and the side effects of HIV infection
  • Vanadyl sulfate can inhibit PTP- IB but its toxicitv prevents chronic administration and widespread acceptance
  • vanadvl sulfate can be used in such small dosages that it will not be toxic
  • the present composition works synergisticaliy to enhance signaling by stimulating PI-3k with alpha-hpoic acid and by increasing the amount of phosphorvlated IRS- 1 with vanadvl sulfate which maintains high levels of insulin receptor kinase activity (see Figure 1 ) Attacking the insulin activated cascade of events in at two different places by administering by vanadyl sulfate and alpha-hpoic acid, permits administration of lower dosages of vanadyl sulfate, thereby reducing the potential for adverse side effects
  • the combination of vanadyl sulfate, alpha-hpoic acid and tau ⁇ ne works synergisticaliy to mimic not only insulin's glucose- normalizing properties but also insulin's lipid-lowe ⁇ ng properties
  • the activation of the phosphodiesterase and production of c-AMP is independent of the tyrosine phosphorvlation of IRS- 1 and subsequent PI-3k activation
  • tau ⁇ ne and its effect on c- AMP provides s ⁇ nergistic lowering of hpids when combined with ⁇ anadyl sulfate and alpha- lipoic acid
  • the current inv ention is designed to normalize insulin action in both glucose tolerance and weight management
  • the current invention may be consumed by healthy persons wishing to decrease their odds of (l) developing NIDDM (n) exhibiting high serum hpoprotein levels and (in) gaining weight on high fat diets
  • v anadvl sulfate lipoic acid and tau ⁇ ne suggested bv the present invention is unique (1) it prov ides a dietan, formulation for the maintenence of normal insulin action at the insulin receptor that can be consumed by healthy persons as well as diabetics; (ii) it can be taken orally; (ii) it maintains its insulin-sparing activity over many months; (iv) it normalizes serum glucose levels; (v) it normalizes serum lipoprotein levels; (vi) it is safe over long periods of time; (vii) it can be used to maintain normal body weight on high-fat diets; and (viii) it can be cost-effective.
  • HTV-infected persons can be treated with the present formulations to normalize insulin sensitivity and prevent the abnormal redistribution of fat.
  • protease therapy for the treatment of HIV infection, persons may now live with the infection for a substantially longer period of time.
  • a syndrome similar to type II diabetes has been observed among these long-term survivors where fat is abnormal distributed and insulin sensitivity is decreased.
  • estimates of the prevalence of this svndrome range from 20 to 70 percent in the HIV-infected population. While it is not known whether this syndrome is due to the combinations of anti-HIV drugs used or to changes in metabolism induced by the virus, the present methods and formulations can be used to treat it, by normalizing insulin sensitivity and fat distribution.
  • Vanadyl sulfate, alpha-lipoic acid and taurine can be obtained commercially, for example, as pharmaceutical grade preparations with a purity of greater than
  • Vanadyl sulfate can be purchased from Spectrum Chemicals MFG, Corp (Gardena, CA).
  • Alpha-lipoic acid can be obtained from Technical Sourcing International, (Missoula, MT) and taurine can be obtained from Premium Ingredients, Ltd. The currently proposed formulation of these three agents does not exist commercially.
  • a daily dose (mg/kg-day) of the present dietary supplement would be formulated to deliver per kg body weight of the mammal the following active ingredients within the suggested ranges: (a) about 0.7 ⁇ g/kg to 1.4 mg/kg vanadyl sulfate; (b) about 1.4 to 71 mg kg alpha-lipoic acid; and (c) about 7 to 43 mg/kg taurine.
  • the relative amount of the individual components would vary to optimize cost-effectiveness and biochemical svnergy.
  • the present dietary supplement mav include complementary herbs v arious additives such as other vitamins and minerals as well as inert ingredients such as talc and magnesium stearate that are standard excipients in the manulacture ol tablets and capsules
  • complementary herbs v arious additives such as other vitamins and minerals as well as inert ingredients such as talc and magnesium stearate that are standard excipients in the manulacture ol tablets and capsules
  • Other ingredients to affect the manufacture of this formulation as a dietary bar or functional food would obviously include flavorings sugars modified starches, grain products as well as fats and oils
  • composition of the dietary supplement in capsule form would supply the follow ing amounts of active ingredients per kg body weight per day (a) 0 4 mg/kg v anadvl sulfate (b) 3 mg/kg alpha-lipoic acid (c) 14 mg/kg taurine Improvement in glucose utilization in the diabetic state would be expected to occur following one to two doses Additionally the formulation mav be used to support or normalize serum hpoprotein levels in nondiabetic subjects This result would be expected in all mammals within one to two weeks

Abstract

A novel dietary supplement or therapeutic composition is provided that serves to (i) increase the sensitivity of muscle, liver or fat cells to insulin, (ii) maintain normal serum glucose, (iii) decrease serum lipoproteins, and (iv) maintain normal body weight with the consumption of a high pat diet. The supplement can be used by normal, healthy individuals, persons infected with HIV and diabetics. The most preferred composition of the dietary supplement, in capsule form would supply the following amounts of active ingredients per kg body weight per day: (a) about 0.4 mg/kg vanadyl sulfate; (b) about 3.0 mg/kg alpha-lipoic acid; and (c) about 14 mg/kg taurine.

Description

DirTλRY SI ΓPPLΓMFNT CONTAINING VANΛDYI SI I I A I Γ. ALPHA-LΓPOIC A.C ID AND TΛURΓNI
FIELD OF THE INVENTION
The present ιn\ ention relates generally to dietary supplements and more particularly, to a formulation of \ anadyl sulfate. alpha-hpoic acid, and tauπne to augment or normalize cellular t rosine phosphorvlation responses to insulin thereby decreasing catabolic activity in the diabetic state and decreasing serum hpoproteins and maintaining normal bodv weight in diabetic. HIV-infected and healthy humans and animals
B ^CKGROUND Of THE INVENTION
The actions of insulin are initiated bv its binding to insulin receptor a disulfide-
1 > bonded heterotetrameπc membrane protein (Figure 1 ) Insulin binding causes conformational changes in insulin receptor that lead to autophosphorvlation of the receptor and activation of the receptor's intrinsic tvrosine kinase activity The function of the tvrosine kinase of insulin receptor is essential for the biological effects of insulin After autophosphorylation, insulin receptor can phosphorvlate the tyrosine residues of several substrates, including insulin
20 receptor substrate (IRS) proteins, which in turn can activate downstream signaling molecules in the liver and muscle cells
Λ protein tvrosine phosphatase termed PTP-1 B can terminate the signalling cascade initiated bv insulin b\ removing the phosphate from insulin receptor Studies indicate that
2^ increased expression of PTP- 1 B in mice gives rise to a form of insulin resistance termed tvpe
2 non-insulin dependent diabetes melhtus (NIDDM) NIDDM is a complex disease characterized b\ progressive development of insulin resistance and defects in insulin secretion, which often leads to overt hvperglycemia On the other hand, some data indicate that mice lacking the PTP- 1 B gene are more sensitive to insulin s blood glucose-lowering
A effects than are control animals and thesePTP-lB defectivemice appeartobe more resistant to weight gain when consuming a high-fat diet Elcheblv et al 238 Sen NU 1 ^44-1548 ( 1999) Vanadate is known to be an inhibitor of many phosphatases Some researchers have proposed that vanadate administration may mimic the activity of insulin For example, U S patent 5 550 1 13 and U S patent 5 888 993 disclose vanadium salts for blood sugar regulation U S Patent 5 885 980 and U S Patent 5,614,224 disclose vanadium salts for the treatment of diabetes
Howe er vanadvl sulfate is not widely used to mimic the activity of insulin because chronic administration of vanadate can be toxic Vanadyl sulfate has been shown to induce chromosomal damage and mitotic recombination in the fruit fly Vanadyl sulfate can induce pulmonary inflammation in rats when inhaled In vitro studies of bovine papilloma virus
DNA-tranfected C3H/10T1/2 cells have demonstrated that vanadvl sulfate possess tumor promotion actix itv
To avoid the toxic build-up of vanadate, some researchers suggest administering it intermittentlv For example U S Patent 5 730,988 to Womack (Mar 24 1998) discloses administration of nutritional supplements containing a source of vanadate in a "Phase I" supplementation program and lipoic acid and Gymnema sylvestre in a "Phase II" supplementation cycle
Given the potential usefulness of vanadvl sulfate in the treatment ot diabetes it would be desirable to administer compositions containing vanadvl sulfate to diabetic patients, HIV- mfected and normal individuals wishing to minimize their risk of developing NEDDM, if the undesirable side effects of vanadate could be avoided
AJpha-hpoic acid has been studied as a potential treatment for improving glucose metabolism L S Patent 5 693 664 to Wessel et al (Dec 2, 1997) discloses the R-(+) enantiomer of alpha- poic acid and its metabolites for the treatment of diabetes A formulation of DL-lipoic acid is described in U S Patent 5 599 835 to Fischer (Feb 4 1997) for treatment of a metabolic aberration of the multi-enzvme complex of pyruvate dehvdrogenase which is symptomatic of diabetes mellitus Tauπne is a conditionally essential nutrient, important during mammalian development In vitro studies indicate that tauπne may have insulin-like activities that are mediated through the activation of c-AMP
Hence while certain compounds are thought to separately mimic some of the activities of insulin, no non-toxic formulation of several compounds which provides a more complete range of insulin-like activities has been developed. The ideal formulation would (1) increase cell sensitivity to insulin, (n) maintain normal serum glucose, (in) decrease hypertπglyceπdemia and/or hpoproteins, and (iv) maintain normal body weight even with consumption of a high fat diet
SUMMARY OF TEE INVENTION
In accordance with the present invention a dietary supplement is provided that comprises vanadvl sulfate alpha-hpoic acid, and tauπne The present supplement (1) increases cell sensitivity to insulin, (n) maintains normal serum glucose, (in) decreases hypertπglyceπdemia and/or hpoproteins, and (iv) maintains normal body weight even with consumption of a high fat diet The supplement can be used by normal, healthy individuals as well as diabetics or persons infected with the HIV virus
The present invention also provides a method of dietary supplementation in animals which includes administering to an animal suffering symptoms of diabetes a composition including synergisticaliy effective amounts of vanadyl sulfate alpha-hpoic acid and tauπne and continuing administration of the composition until the svmptoms are reduced
The present inv ention further provides a method of dietary supplementation in animals which includes administering to an animal a composition which includes svnergistically effective amounts of v anadvl sulfate. alpha-hpoic acid and tauπne and continuing administration of the composition until normalization of serum glucose is achieved
The present invention still further prov ides a method of dietary supplementation in animals which includes administering to an animal a composition w hich includes synergisticaliy effective amounts of vanadvl sulfate, alpha-hpoic acid and tauπne and continuing administration of the composition until normalization of serum tπglyeπceds is achieved
The present invention additionally provides a method of treating obesity in an animal which includes administering to an animal a composition including synergisticaliy effective amounts of vanadvl sulfate, alpha-hpoic acid and tauπne
According to the present invention, the animal is a mammal selected from the group consisting of humans nonhuman primates, dogs, cats, horses or cattle Administration can be bv anv method available to the skilled artisan, for example, bv oral and by injection routes
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 provides a schematic diagram illustrating, according to the present invention, how the components of the present formulation vanadvl sulfate. alpha-hpoic acid and tauπne, can act together to enhance augment or 3 pare [modulate9] the effect of insulin on liver, muscle or fat cells As illustrated, the tyrosine kinase signaling pathway is initiated through the interaction of insulin and the insulin receptor (IR), leading to the phosphorylation of insulin receptor PTP-1B can remove the phosphate from insulin receptor, thereby inactivating its kinase activity Vanadvl sulfate can block the activity of phosphatases like
PTP-1B thereby preventing the dephosphorvlation of insulin receptor Tauπne can activate cyclic .AMP Alpha-hpoic acid (Lipoate) can augment glucose uptake and lower serum lipid levels The result is that this novel combination of ingredients enhances augments or 3parcs [modulates9] the effect of insulin on liver, muscle and/or fat cells
DETAILED DESCRIPTION OF THE INVENTION
The present invention provides a composition that can be taken as a dietary supplement which includes v anadvl sulfate alpha-hpoic acid, and tauπne Each of these individual components affect the insulin-induced chain of activities to some degree In combination the resulting dietary supplement addresses the decreased insulin sensitivity and secondary pathologies associated with diabetes, HIV infection normal aging and with NIDDM
According to the present invention, compounds which inhibit PTP- 1 B can be used to prevent and treat obesitv diabetes and the side effects of HIV infection Vanadyl sulfate can inhibit PTP- IB but its toxicitv prevents chronic administration and widespread acceptance However when combined with other compounds which have insulin-like activities, vanadvl sulfate can be used in such small dosages that it will not be toxic
In another embodiment, the present composition works synergisticaliy to enhance signaling by stimulating PI-3k with alpha-hpoic acid and by increasing the amount of phosphorvlated IRS- 1 with vanadvl sulfate which maintains high levels of insulin receptor kinase activity (see Figure 1 ) Attacking the insulin activated cascade of events in at two different places by administering by vanadyl sulfate and alpha-hpoic acid, permits administration of lower dosages of vanadyl sulfate, thereby reducing the potential for adverse side effects
Moreover according to the present invention, the combination of vanadyl sulfate, alpha-hpoic acid and tauπne works synergisticaliy to mimic not only insulin's glucose- normalizing properties but also insulin's lipid-loweπng properties As seen in Figure 1 , the activation of the phosphodiesterase and production of c-AMP is independent of the tyrosine phosphorvlation of IRS- 1 and subsequent PI-3k activation Thus, tauπne and its effect on c- AMP provides s\ nergistic lowering of hpids when combined with \ anadyl sulfate and alpha- lipoic acid
The current inv ention is designed to normalize insulin action in both glucose tolerance and weight management In these regards, the current invention may be consumed by healthy persons wishing to decrease their odds of (l) developing NIDDM (n) exhibiting high serum hpoprotein levels and (in) gaining weight on high fat diets
The combination of v anadvl sulfate lipoic acid and tauπne suggested bv the present invention is unique (1) it prov ides a dietan, formulation for the maintenence of normal insulin action at the insulin receptor that can be consumed by healthy persons as well as diabetics; (ii) it can be taken orally; (ii) it maintains its insulin-sparing activity over many months; (iv) it normalizes serum glucose levels; (v) it normalizes serum lipoprotein levels; (vi) it is safe over long periods of time; (vii) it can be used to maintain normal body weight on high-fat diets; and (viii) it can be cost-effective.
According to the present invention, HTV-infected persons can be treated with the present formulations to normalize insulin sensitivity and prevent the abnormal redistribution of fat. With the addition of protease therapy for the treatment of HIV infection, persons may now live with the infection for a substantially longer period of time. A syndrome similar to type II diabetes has been observed among these long-term survivors where fat is abnormal distributed and insulin sensitivity is decreased. Currently, estimates of the prevalence of this svndrome range from 20 to 70 percent in the HIV-infected population. While it is not known whether this syndrome is due to the combinations of anti-HIV drugs used or to changes in metabolism induced by the virus, the present methods and formulations can be used to treat it, by normalizing insulin sensitivity and fat distribution.
Manufacturing and sale of the present formulations should comply with all government regulations. Vanadyl sulfate, alpha-lipoic acid and taurine can be obtained commercially, for example, as pharmaceutical grade preparations with a purity of greater than
95% by weight. Vanadyl sulfate can be purchased from Spectrum Chemicals MFG, Corp (Gardena, CA). Alpha-lipoic acid can be obtained from Technical Sourcing International, (Missoula, MT) and taurine can be obtained from Premium Ingredients, Ltd. The currently proposed formulation of these three agents does not exist commercially.
Preferably, a daily dose (mg/kg-day) of the present dietary supplement would be formulated to deliver per kg body weight of the mammal the following active ingredients within the suggested ranges: (a) about 0.7 μg/kg to 1.4 mg/kg vanadyl sulfate; (b) about 1.4 to 71 mg kg alpha-lipoic acid; and (c) about 7 to 43 mg/kg taurine. The relative amount of the individual components would vary to optimize cost-effectiveness and biochemical svnergy. In addition to vanadv l sulfate alpha-lipoic acid, and taurine the present dietary supplement mav include complementary herbs v arious additives such as other vitamins and minerals as well as inert ingredients such as talc and magnesium stearate that are standard excipients in the manulacture ol tablets and capsules Other ingredients to affect the manufacture of this formulation as a dietary bar or functional food would obviously include flavorings sugars modified starches, grain products as well as fats and oils
EXAMPLE 1
The most preferred composition of the dietary supplement in capsule form would supply the follow ing amounts of active ingredients per kg body weight per day (a) 0 4 mg/kg v anadvl sulfate (b) 3 mg/kg alpha-lipoic acid (c) 14 mg/kg taurine Improvement in glucose utilization in the diabetic state would be expected to occur following one to two doses Additionally the formulation mav be used to support or normalize serum hpoprotein levels in nondiabetic subjects This result would be expected in all mammals within one to two weeks
Thus there has been disclosed a dietary supplement comprising vanadvl sulfate alpha- lipoic acid and taurine It will be readilv apparent to those skilled in the art that various changes and modifications of an obvious nature mav be made without departing from the spirit of the invention and all such changes and modifications are considered to fall within the scope of the invention as defined bv the appended claims Such obvious changes and modifications would include but not be limited to the incipient ingredients added to affect the capsule tablet snack bar or powder manufacturing processes as well as the addition of v itamins nutrients and herbs

Claims

WHAT IS CLAIMED IS
1 A composition comprising vanadvl sulfate, alpha-lipoic acid and taurine
2 A composition designed to deliver per kg body weight per dav the following components
(a) about 0 7 μg/kg to about 1 4 mg kg vanadyl sulfate,
(b) about 1 4 to about 71 mg kg alpha-lipoic acid, and
(c) about 7 to about 43 mg/kg taurine
3 A composition designed to deliver per kg body weight per dav the following components
(a) about 0 4 mg/kg vanadvl sulfate,
(b) about 3 0 mg/kg alpha-lipoic acid, and
(c) about 14 mg/kg taurine
4 The composition of any one of Claims 1 , 2 or 3 wherein said vanadyl sulfate is pharmaceutical grade with a puritv of greater than 95% by weight
5 The composition ofanv one of Claims 1 2 or 3 wherein said alpha-lipoic acid is pharmaceutical grade with a puritv of greater than 95% bv weight
6 The composition of any one of Claims 1 , 2 or 3 wherein said tauπne is pharmaceutical grade with a puritv of greater than 95% bv weight
7 The composition of anv one of Claims 1 , 2 or 3 which fuπher comprises medium chain tnglycerides and wherein said medium chain tnglycerides are composed of fattv acids chains of 10 to 14 carbons and are pharmaceutical grade with a puritv of greater than 95% bv weight
8 The composition of anv one of Claims 1 2 or 3 which further comprises added vitamins
9 The composition of anv one of Claims 1. 2 or 3 which further comprises added essential minerals
10 The composition of any one of Claims 1 , 2 or 3 which further comprises added proteins
1 1 The composition of any one of Claims 1, 2 or 3 which further comprises additional fats
12 The composition ofany one of Claims 1 , 2 or 3 which further comprises added carbohydrates
13 The composition of any one of Claims 1 , 2 or 3 which further comprises added flavoring agents
14 The composition ofany one of Claims 1 , 2 or 3 which further comprises herbs
15 The composition of anv one of Claims 1 2 or 3 which further comprises an extract of herbs
16 The composition of any one of Claims 1 , 2 or 3 which further comprises an extract of plants
17 The composition of any one of Claims 1. 2 or 3 which further comprises an extract of microorganisms
18 The composition of anv one of Claims 1. 2 or 3 which further comprises a pharmaceuticallv acceptable carrier 19 The composition of anv one of Claims 1 2 or 3 in anv one of the following forms tablet, capsule, powder liquid suspension chewable bar, or a component of food
20 A method of dietary supplementation in animals comprising administering to an animal suffering symptoms of diabetes a composition comprising synergisticallv effective amounts of vanadvl sulfate alpha-lipoic acid and taurine and continuing administration of the composition until svmptoms of diabetes are reduced
21 A method of dietary supplementation in animals comprising administering to an animal a composition comprising synergisticaliy effective amounts of vanadvl sulfate, alpha-lipoic acid and taurine and continuing administration of the composition until normalization of serum glucose is achieved
22 A method of dietary supplementation in animals comprising administering to an animal a composition comprising synergisticaliy effective amounts of vanadvl sulfate, alpha-lipoic acid and taurine and continuing administration of the composition until normalization of serum tπglyeπceds is achieved
23 A method of treating obesity in an animal which comprises administering to an animal a composition comprising synergisticallv effective amounts of vanadvl sulfate alpha-lipoic acid and taurine
24 A method of dietary supplementation in animals comprising administering to an animal suffering from HIV infection a composition comprising synergisticallv effective amounts of vanadv 1 sulfate alpha-lipoic acid and tauπne and continuing administration of the composition until svmptoms of HIV infection are reduced
25 A method of inhibiting PTP-1 B in animals comprising administering to an animal a composition comprising synergisticallv effectiv e amounts of vanadvl sulfate alpha- lipoic acid and taurine and continuing administration of the composition to inhibit PTP-1B 26 A method of stimulating PI-3k in animals comprising administering to an animal a composition comprising synergisticallv effective amounts of vanadyl sulfate, alpha- lipoic acid and taurine and continuing administration of the composition to stimulate PI-3k
27 The method of any one of Claims 20-26 wherein the animal is a mammal selected from the group consisting of humans, HIV-infected humans, nonhuman primates, dogs, cats, horses or cattle
28 The method of any one of Claims 20-26 wherein administration is oral
29 The method ofany one of Claims 20-26 wherein administration is by injection
PCT/US2000/015196 1999-06-02 2000-06-02 A dietary supplement containing vanadyl sulfate, alpha-lipoic acid, and taurine WO2000072854A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU57255/00A AU5725500A (en) 1999-06-02 2000-06-02 A dietary supplement containing vanadyl sulfate, alpha-lipoic acid, and taurine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13708099P 1999-06-02 1999-06-02
US60/137,080 1999-06-02

Publications (1)

Publication Number Publication Date
WO2000072854A1 true WO2000072854A1 (en) 2000-12-07

Family

ID=22475744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/015196 WO2000072854A1 (en) 1999-06-02 2000-06-02 A dietary supplement containing vanadyl sulfate, alpha-lipoic acid, and taurine

Country Status (2)

Country Link
AU (1) AU5725500A (en)
WO (1) WO2000072854A1 (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056402A2 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
WO2002013814A1 (en) * 2000-08-11 2002-02-21 The Lawson Health Research Institute Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
EP1330957A2 (en) * 2002-01-15 2003-07-30 Karl-Heinz Bauer Nutritional supplement
WO2003101469A1 (en) * 2002-06-04 2003-12-11 Metaproteomics, Llc An oral composition with insulin-like activities and methods of use
KR100427637B1 (en) * 2001-06-05 2004-04-27 이인규 Agent increasing energy expenditure of the cell
US8715717B2 (en) * 2003-09-05 2014-05-06 Hill's Pet Nutrition, Inc. Composition for animal consumption
US20180092878A1 (en) * 2015-05-21 2018-04-05 Ophtalmis Monaco Combination of lipoic acid and taurine as osmoprotective agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751085A (en) * 1984-08-29 1988-06-14 Gaull Gerald E Human nutritional compositions containing taurine and vitamins and/or minerals
US5693664A (en) * 1993-12-21 1997-12-02 Asta Medica Aktiengesellschaft Use of R-(+)-α-lipoic acid, R-(-)dihydrolipoic acid and metabolites in the form of the free acid or salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae
US5730988A (en) * 1995-04-20 1998-03-24 Lynntech, Inc. Nutritional supplements for improving glucose metabolism

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4751085A (en) * 1984-08-29 1988-06-14 Gaull Gerald E Human nutritional compositions containing taurine and vitamins and/or minerals
US5693664A (en) * 1993-12-21 1997-12-02 Asta Medica Aktiengesellschaft Use of R-(+)-α-lipoic acid, R-(-)dihydrolipoic acid and metabolites in the form of the free acid or salts or esters or amides for the preparation of drugs for the treatment of diabetes mellitus as well as of its sequelae
US5730988A (en) * 1995-04-20 1998-03-24 Lynntech, Inc. Nutritional supplements for improving glucose metabolism

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001056402A2 (en) * 2000-02-01 2001-08-09 Muscletech Research And Development Inc. Alpha lipoic acid based food supplement to increase lean muscle mass and strength
WO2001056402A3 (en) * 2000-02-01 2002-08-22 Muscletech Res And Dev Inc Alpha lipoic acid based food supplement to increase lean muscle mass and strength
WO2002013814A1 (en) * 2000-08-11 2002-02-21 The Lawson Health Research Institute Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
WO2002013813A1 (en) * 2000-08-11 2002-02-21 The Lawson Health Research Institute Compositions and methods for inhibiting islet dysfunction and autoimmune disorders
KR100427637B1 (en) * 2001-06-05 2004-04-27 이인규 Agent increasing energy expenditure of the cell
EP1330957A2 (en) * 2002-01-15 2003-07-30 Karl-Heinz Bauer Nutritional supplement
EP1330957A3 (en) * 2002-01-15 2003-10-22 Karl-Heinz Bauer Nutritional supplement
WO2003101469A1 (en) * 2002-06-04 2003-12-11 Metaproteomics, Llc An oral composition with insulin-like activities and methods of use
US6733793B2 (en) 2002-06-04 2004-05-11 Metaproteomics, Llc Oral composition with insulin-like activities and methods of use
US8715717B2 (en) * 2003-09-05 2014-05-06 Hill's Pet Nutrition, Inc. Composition for animal consumption
US20180092878A1 (en) * 2015-05-21 2018-04-05 Ophtalmis Monaco Combination of lipoic acid and taurine as osmoprotective agent
US11224588B2 (en) * 2015-05-21 2022-01-18 Ophtalmis Monaco Combination of lipoic acid and taurine as osmoprotective agent

Also Published As

Publication number Publication date
AU5725500A (en) 2000-12-18

Similar Documents

Publication Publication Date Title
US6733793B2 (en) Oral composition with insulin-like activities and methods of use
US5932624A (en) Vitamin supplement composition
EP2288364B1 (en) Methods for the treatment or prevention of diabetes mellitus and other metabolic imbalances
EP0969744B1 (en) Nutritional composition for improvements in cell energetics
US20120148685A1 (en) Methods and compositions for treating insulin resistance, diabetes mellitus type 2, metabolic syndrome and related disorders
Weksler-Zangen et al. Glucose tolerance factor extracted from yeast: oral insulin-mimetic and insulin-potentiating agent: in vivo and in vitro studies
US9895375B2 (en) Compositions containing riboflavin and sesamin-class compounds
JP2007536250A (en) Nutritional composition for increasing creatine uptake in skeletal muscle
JPH06510286A (en) Pharmaceutical composition containing 3-guanidinopropionic acid and pioglitazone, glibenclamide or glimepiride
JP2005513107A (en) Compositions containing (-)-hydroxycitric acid, chromium, and gymnemic acid, and methods for improving health factors associated with methods of promoting healthy weight
KR20080038870A (en) Oral compositions for the improvement of obesity and diabetes
US6476071B1 (en) Correcting polymorphic metabolic dysfunction with (−)-hydroxycitric acid
WO2000072854A1 (en) A dietary supplement containing vanadyl sulfate, alpha-lipoic acid, and taurine
KR100304312B1 (en) Zinc Supplemented Prostate Extract
EP2445338A1 (en) Synergistic combination to enhance blood glucose and insulin metabolism
US7416750B1 (en) Composition to provide maintenance and nutritional support in glycemic control deficits
US6599522B2 (en) Triglyceride reducing agent
CN110859307A (en) Composition containing sodium pyruvate and use thereof
US20120231098A1 (en) Weight loss composition
CN113712982B (en) Composition for preventing or treating non-alcoholic fatty liver disease and obesity, and preparation method and application thereof
WO2003055508A1 (en) Composition for the treatment of renal failure or gastric dysfunction of e.g. premature or neonatal mammals
KR102291168B1 (en) Compositions for the prevention or treatment of metabolic diseases containing extracts or fractions of Typha angustifolia
Obeid et al. Postprandial glycogen and lipid synthesis in prednisolone-treated rats maintained on high-protein diets with varied carbohydrate levels
Djuričić et al. Dietary factors and thyroid dysfunction
Đuričić et al. Dijetarni faktori i tiroidna disfunkcija

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP